Slides - Cancer Therapy Advisor

Slides

DARZALEX (daratumumab) for Multiple Myeloma

This slideshow reviews drug information for DARZALEX (daratumumab), indicated for multiple myeloma. Table of Contents Slide 3: Indication, Dosage, and AdministrationSlide 16: Use in Specific PopulationsSlide 19: Clinical PharmacologySlide 23: Warnings and PrecautionsSlide 28: Clinical Safety and EfficacySlide 46: Drug Storage and SupplySlide 49: References  

KEYTRUDA (pembrolizumab) for Non-small Cell Lung Cancer

This slideshow reviews drug information for KEYTRUDA (pembrolizumab), indicated for non-small cell lung cancer. Table of Contents Slide 3: Indication, Dosage, and AdministrationSlide 11: Use in Specific PopulationsSlide 14: Clinical PharmacologySlide 18: Warnings and PrecautionsSlide 24: Clinical Safety and EfficacySlide 41: Drug Storage and SupplySlide 43: References

KEYTRUDA (pembrolizumab) for Head and Neck Cancer

This slideshow reviews drug information for KEYTRUDA (pembrolizumab), indicated for head and neck cancer. Table of Contents Slide 3: Indication, Dosage, and AdministrationSlide 10: Use in Specific PopulationsSlide 13: Clinical PharmacologySlide 17: Warnings and PrecautionsSlide 22: Clinical Safety and EfficacySlide 28: Drug Storage and SupplySlide 30: References

NINLARO (ixazomib) for Multiple Myeloma

This slideshow reviews drug information for NINLARO (ixazomib), indicated for multiple myeloma. Table of Contents Slide 3: Indication, Dosage, and AdministrationSlide 9: Use in Specific PopulationsSlide 12: Clinical PharmacologySlide 16: Warnings and PrecautionsSlide 22: Clinical Safety and EfficacySlide 28: Drug Storage and SupplySlide 30: References

VENCLEXTA (venetoclax) for Chronic Lymphocytic Leukemia

  This slideshow reviews drug information for VENCLEXTA (venetoclax), indicated for chronic lymphocytic leukemia. Table of Contents Slide 3: Indication, Dosage, and AdministrationSlide 14: Use in Specific PopulationsSlide 17: Clinical PharmacologySlide 23: Warnings and PrecautionsSlide 19: Clinical Safety and EfficacySlide 27: Drug Storage and SupplySlide 33: References

SUTENT (sunitinib) for GIST, Advanced RCC and Advanced pNET

This slideshow reviews drug information for SUTENT (sunitinib), indicated for gastrointestinal stream tumors (GISTs), advanced renal cell carcinoma (RCC), and pancreatic neuroendocrine tumors (pNETs).  Table of Contents Slide 3: Indication, Dosage, and AdministrationSlide 7: Use in Specific PopulationsSlide 9: Clinical PharmacologySlide 13: Warnings and PrecautionsSlide 19: Clinical Safety and EfficacySlide 33: Drug Storage and SupplySlide…

TAGRISSO (osimertinib) for Metastatic Non-small Cell Lung Cancer

This slideshow reviews drug information for TAGRISSO (osimertinib), indicated for metastatic non-small cell lung cancer (NSCLC). Table of Contents Slide 3: Indication, Dosage, and AdministrationSlide 8: Use in Specific PopulationsSlide 11: Clinical PharmacologySlide 16: Warnings and PrecautionsSlide 20: Clinical Safety and EfficacySlide 26: Drug Storage and SupplySlide 28: References

INTRON A (interferon alfa-2b) for Malignant Melanoma

This slideshow reviews drug information for INTRON A (interferon alfa-2b), indicated for malignant melanoma. Table of Contents Slide 3: Indication, Dosage, and AdministrationSlide 10: Use in Specific PopulationsSlide 13: Clinical PharmacologySlide 17: Warnings and PrecautionsSlide 22: Clinical Safety and EfficacySlide 29: Drug Storage and SupplySlide 31: References

PORTRAZZA (necitumumab) for Metastatic Squamous Non-small Cell Lung Cancer

This slideshow reviews drug information for PORTRAZZA (necitumumab), indicated for metastatic squamous non-small cell lung cancer. Table of Contents Slide 3: Indication, Dosage, and AdministrationSlide 9: Use in Specific PopulationsSlide 11: Clinical PharmacologySlide 15: Warnings and PrecautionsSlide 20: Clinical Safety and EfficacySlide 26: Drug Storage and SupplySlide 28: References

ALECENSA (alectinib) for Metastatic Non-small Cell Lung Cancer

This slideshow reviews drug information for ALECENSA (alectinib), indicated for metastatic non-small cell lung cancer.Table of ContentsSlide 3: Indication, Dosage, and AdministrationSlide 10: Use in Specific PopulationsSlide 13: Clinical PharmacologySlide 17: Warnings and PrecautionsSlide 22: Clinical Safety and EfficacySlide 29: Drug Storage and SupplySlide 31: References

Next hm-slideshow in Slides